Research
Metabolic adaptation
Therapies such as thiazolidinedione, insulin secretagogue, and insulin are less suitable for individuals with obesity and T2D as they are associated with weight gain.
Clinicians should avoid prescribing therapies that promote weight gain in obese T2D patients.
StrongRefutesmedium confidence
Therapies such as thiazolidinedione, insulin secretagogue (sulfonylurea and meglitinide), and insulin are less suitable for individuals with obesity and T2D as they are associated with weight gain.
Why this rating
The claim is based on clinical observations noted in the abstract.
Source
Choice of Therapy in Obese Type 2 Diabetes
VivekaP Jyotsna et al. · Chronicle of Diabetes Research and Practice · 2022
review
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →